No retraction, correction or concern found when last checked on Oct 17, 2026.
The GenomeAsia 100K Project enables genetic discoveries across Asia
GenomeAsia100K Consortium, Jeffrey D. Wall, Eric W. Stawiski and 67 more
Nature · 2019 · CC BY
Abstract
The underrepresentation of non-Europeans in human genetic studies so far has limited the diversity of individuals in genomic datasets and led to reduced medical relevance for a large proportion of the world’s population. Population-specific reference genome datasets as well as genome-wide association studies in diverse populations are needed to address this issue. Here we describe the pilot phase of the GenomeAsia 100K Project. This includes a whole-genome sequencing reference dataset from 1,739 individuals of 219 population groups and 64 countries across Asia. We catalogue genetic variation, population structure, disease associations and founder effects. We also explore the use of this dataset in imputation, to facilitate genetic studies in populations across Asia and worldwide.
Full text
From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.
Main
The underrepresentation of non-European individuals in human genetic studies limits the applicability of the results for a large proportion of the world’s population. Reference genome datasets– are needed to characterize population-specific variation, enable efficient imputation of variants that are not directly genotyped, and extend genome-wide association studies (GWAS) to additional populations. The value of population-specific reference datasets is well recognized and projects based in the United States and Europe have provided deep characterization of specific populations (for example, Ashkenazi Jews and individuals from the Netherlands and Iceland) and, in particular, data from individuals of Nordic countries have provided examples of how reference genome datasets can be used to drive comprehensive genetic studies across an entire population. In Africa, populations show complex genetic patterns, smaller blocks of linkage disequilibrium and higher levels of heterozygosity, which provides unique value for genetic studies. Across the continent, early reference genome datasets for diverse populations are being built as part of H3Africa and other studies,. A Korean reference genome as well as Japanese and Chinese reference genome datasets have been created, and the formation of large biobanks such as BioBank Japan and the China Kadoorie Biobank will accelerate the pace of discovery of disease associations across east Asia.
A shared recognition of the value of coordinated efforts and the need for reference genome datasets that would be useful for the complex populations of Asia has led to the formation of the GenomeAsia consortium (http://www.genomeasia100k.com). The consortium serves to facilitate and coordinate sequencing efforts among consortium members to maximize the value of the genomic sequence data that is produced and to facilitate efforts by national or other regional groups. Here we describe the GenomeAsia Pilot (GAsP) project, which consists of analyses of the whole-genome sequencing data of 1,739 individuals from 219 population groups across Asia, with the ultimate goal of providing a useful genomic resource and facilitating genetic studies in Asia. We use the data that was generated in this pilot to analyse population structure and history, and as the basis for designing larger-scale genomic studies. Furthermore, we explore disease-associated loci as an initial comparison of differences between populations. We show that the variant data produced by this project improve variant filtering for the discovery of disease-associated genes of rare diseases. We show that Asia has sizable founder populations and that further studies in these populations may be useful for the discovery of rare-disease-associated genes. We also report an initial survey of loss-of-function alleles found in the GAsP project.
The GAsP dataset
For the GAsP project, we generated 1,267 high-coverage (average 36×) whole-genome sequences and analysed these together with 596 publicly available human genome sequences from previous sequencing studies (Supplementary Information 1, 2 and Supplementary Tables 1a–c, 2a). The 1,739 samples were enriched for individuals from population isolates to capture the broadest wealth of genetic diversity; the dataset includes 598 sequences from India, 156 from Malaysia, 152 from South Korea, 113 from Pakistan, 100 from Mongolia, 70 from China, 70 from Papua New Guinea, 68 from Indonesia, 52 from the Philippines, 35 from Japan and 32 from Russia (Fig. 1a–c and Supplementary Table 1a–c). To facilitate comprehensive and comparative analysis of human genetic variation, we included sequencing data from African, European and American samples (Supplementary Table 1a, b). The sequenced samples originate from 7 global regions, 64 different countries of origin and 219 population groups. About 80% of the samples come from Asia and emphasize population groups that are underrepresented in previous genetic studies (Fig. 1a, b, Supplementary Tables 1a–c, 2b and Supplementary Information 1, 2). Each global region and population group was assigned a unique three-letter code for future reference (see Supplementary Table 1a for three-letter code designations). Within Asia, the sampling of many distinct population groups allowed us to analyse the relationship between geography, physical characteristics and genetic variation. In south and southeast Asia, in particular, we sampled across diverse populations to gather new insights into how groupings defined on the basis of caste and language relate to genetic diversity, admixture with extinct hominins and other genetically described characteristics.
Population structure
Knowledge of the complex history of Asian populations informs optimal sampling for larger-scale biomedical sequencing efforts. We applied standard approaches for detecting recent positive selection, quantifying the population structure and inferring the history of the different populations, including principal component analysis, multiple sequentially Markovian coalescent (MSMC), ADMIXTURE, FST, uniparental analyses and the analysis of the Y chromosome and mitochondrial haplogroups (Fig. 2, Extended Data Fig. 1 and Supplementary Information 3–10). Our results generally recapitulate the broad inferences of previous studies, and ADMIXTURE plots show complex structure within south and southeast Asia (Fig. 2a). In particular, India, Malaysia and Indonesia contain multiple ancestral populations as well as multiple admixed groups. On the basis of MSMC cross-coalescence rates, which reflect the increase in coalescence times of haplotypes sampled from different populations relative to haplotypes sampled from the same population, we estimate that the oldest population splits in southeast Asia and Oceania involve Melanesians and/or Negritos, who show a substructure from approximately 40 thousand years ago and evidence of separation around 20–30 thousand years ago (Extended Data Fig. 1b and Supplementary Information 3). The population structure provides genetic information on classically defined population groups to aid future studies. For example, using multiple analytical approaches (Supplementary Information 3, 6), we confirmed that the anthropologically classified ‘Negrito’ groups from India, Malaysia and the Philippines, are genetically more closely related to their geographical neighbours than they are to other Negrito groups,, suggesting that dark skin colour is probably an environmental adaptation (for example, to high levels of solar radiation) and not an indicator of shared ancestry.
Our dense sampling of Asian populations enables the examination of Denisovan admixture in greater detail than has been previously possible, providing information about population splits or in-flows that occurred at or after the time of admixture (Supplementary Information 10). Our estimates of Denisovan ancestry were highest in Melanesians and the Aeta, intermediate in the Ati and groups from the Indonesian island of Flores, and low (but still significantly greater than 0) in most south, east and southeast Asian populations. We found high levels of Denisovan ancestry in Philippine Negrito groups but not in Malay or Andaman Negritos; these results are qualitatively similar to what was found in a previous study that was based on single-nucleotide polymorphism (SNP) arrays. The high levels of Denisovan ancestry in Melanesians and the Aeta are consistent with an admixture event into a population that is ancestral to both; however, two lines of evidence suggest that the ancestors of the Aeta experienced a second Denisovan admixture event. First, multiple analyses found that the Aeta are genetically more similar to populations without appreciable Denisovan ancestry (for example, Igorot, Malay and Malay Negrito groups) than they are to Melanesians (Supplementary Information 3, 6). This can be explained by more recent gene flow from other populations without Denisovan ancestry. However, such gene flow would reduce the levels of Denisovan admixture below that found in Melanesians. More directly, we find that putative Denisovan haplotypes that are unique to the Aeta (n = 962) are significantly longer than putative Denisovan haplotypes shared between Aeta and Papuans (n = 596, mean = 16.1 kb compared with mean = 14.1 kb, Mann–Whitney U-test, P ≪ 10−10), or putative Denisovan haplotypes unique to Papuans (n = 727, mean = 16.1 kb compared with mean = 14.9 kb, Mann–Whitney U-test, P ≪ 10−1,000) (Supplementary Information 10), supporting a scenario in which a second admixture event between the Aeta and Denisovans happened after the separation of the Aeta and Melanesians. Two distinct Denisovan admixture events are most consistent with Homo sapiens and Denisovans interacting within southeast Asia, making it likely that admixture occurred within Sundaland (Fig. 2b) or even farther east,.
A recent study found a slightly increased amount of Denisovan ancestry in south Asians compared with a priori expectations. We examined whether this was correlated with either language or social and/or caste status. South Asian samples were grouped into individuals who speak Indo-European languages and individuals who speak non-Indo-European languages (excluding individuals who speak Tibeto-Burman languages), as well as four social or cultural groups: tribal (Adivasi) groups, lower-caste groups, high-caste groups and Pakistani groups (Indo-European language speaking only). We found that the average levels of Denisovan ancestry were significantly different between the four social or cultural groups (Mann–Whitney U-test, P < 10−8 for all pairwise comparisons; Fig. 2c and Supplementary Information 10). Our results are consistent with the scenario that Indo-European-speaking migrants who entered the subcontinent from the northwest admixed with an indigenous South Asian (ancestral south Indian), group who had higher levels of Denisovan ancestry.
Medical relevance
We evaluated the use of GAsP dataset in disease-associated genetic studies and medically relevant applications to determine how the results of larger continuing GenomeAsia studies can be used to improve human health (Supplementary Table 4a). We annotated high-quality variants using public databases including ExAC (Exome Aggregation Consortium), gnomAD, 1000 Genomes Project, ESP (NHLBI GO Exome Sequencing Project) and dbSNP (Extended Data Fig. 2) and focused on coding-sequence variants. Overall 23% of protein-altering variants in GAsP were not found in these data sources. As expected the majority of coding variants were singletons or very rare (Extended Data Fig. 2). However, the absolute numbers of novel variants with a minor allele frequency (MAF) ≥ 0.1% within our pan-Asian dataset is large (n = 194,585), and these are frequent enough to be of relevance for large-scale genetic association studies. We also searched for variants present at low frequency in the overall dataset that are present at significantly higher allele frequencies in one or more of the population groups. We found an additional 144,329 novel variants with MAF > 1% in the full GAsP dataset that were present at a frequency of greater than 1% within populations grouped by geography; South Asia, Southeast Asia, Northeast Asia or Oceania (see Supplementary Table 1a for description of samples and population groups included in each geographically defined set). These geographical regions contain many diverse population groups, and additional studies are needed to characterize patterns of genetic variation in these groups and disease relevance.
In rare disease genetics, databases are used to filter based on allele frequency with the idea that common alleles are unlikely to be responsible for rare highly penetrant disorders; however, in the absence of appropriate population reference datasets, allele frequencies can be misclassified and may lead to false disease associations. We explored whether the GAsP variant dataset can improve the ability to identify disease-relevant variants in Asian cohorts. We analysed 152 exomes from individuals participating in the Indian Maturity Onset Diabetes in the Young (MODY) project. When both the gnomAD and GAsP datasets were used for filtering (MAF > 0.1%), we reduced the set of remaining candidate variants by approximately twofold in comparison to using the gnomAD dataset alone (Fig. 3a). In this process, we identified a common population polymorphism in NEUROD1 (H241Q) that is probably benign but that was previously reported to be medically relevant,. We annotated variants that were identified in the GAsP dataset against the Human Gene Mutation Database (HGMD) disease-causing pathological and ClinVar pathogenic variants. This analysis identified 732 variants (686 SNPs and 46 insertions or deletions (indels)) in 514 genes (Fig. 3b, Supplementary Table 4b, c and Supplementary Information 11). We compared the 732 pathogenic variants against the gnomAD, ExAC, 1000Genomes, ESP, dbSNP, ALSPAC, TwinsUK and 1000Japanese databases to remove variants that occurred at >1%, focused on those with allele frequencies >0.15% in GAsP (38 variants), and reviewed them against the criteria defined by the American College of Medical Genetics (ACMG). This resulted in reclassification of 11 of the 38 variants (Supplementary Table 4d). We examined the geographical distribution of the remaining, revalidated but high-frequency, pathogenic disease-associated variants. As expected, most of these variants were highly enriched in Asia. For example, an HBB variant (chromosome 11: 5248155 c.92+5G>C) associated with β-thalassaemia is found almost exclusively in south Asians and at a lower frequency in southeast Asians (Fig. 3c).
We also examined our dataset for novel variants in genes known to be associated with cancer risk. We found 13 unique variants in 6 genes from 17 samples. This included frameshift, stop-gained and essential splice-site mutations in BRCA2 (n = 9), BRCA1 (n = 1), ATM (n = 2), BLM (n = 1), NBN (n = 2) and PMS2 (n = 2) (Fig. 3d and Supplementary Table 4e). Of the two PMS2 essential splice variants, one was found in a Korean sample. Loss-of-function mutations in PMS2 are associated with mismatch repair defects that lead to a higher risk of cancer development. In a separate study of gall bladder cancer, we found the same essential splice site PMS2 mutation (chromosome 7:6043690C>G) in a Korean patient whose gall bladder cancer exhibits microsatellite instability (E.W.S. and S. Seshagiri, manuscript in preparation). Identification of genetic variants that affect drug efficacy and safety through the alteration of pharmacokinetics enables application of individualized treatment–. Variation in drug responses are generally recognized and recommendations for dosing are sometimes guided by apparent or self-reported population identity despite the lack of a rigorous pharmacogenomic basis. We assessed the allele frequencies of key pharmacogenomic variants in our dataset to identify inter-population differences that have potential implications on drug testing and treatment (Fig. 3e, Supplementary Table 4g and Supplementary Information 13).
Carbamezepine, clopidigrel, peginterferon and warfarin showed the largest variation between populations in predicted adverse drug responses with groups ranging from 0 and 100 predicted adverse drug responses. For example, the HLA-B*15:02 variant, associated with risk for development of Steven Johnson syndrome in patients treated with carbamazepine was found to occur at an increased frequency in Austronesian language-speaking populations from southeast Asia (for example, 63% in the Mentawai of West Sumatra; 46.6% in the Nias of North Sumatra) compared with other groups (Supplementary Information 13). There are roughly 400 million individuals who belong to Austronesian groups that are at increased risk for carbamazepine sensitivity, including the vast majority of the people from Indonesia, Malaysia and the Philippines.
Founder populations
Population bottlenecks produce strong founder effects and increased rates of recessive disease. In populations with strong founder effects, the loss-of-function variant frequency spectrum is skewed higher, greatly increasing power of association and providing unique advantages for the identification of genes associated with both rare and complex diseases,. We followed the approach described in a previous study on south Asian populations to characterize the degree to which genomic segments are inherited as identical by descent (IBD) in population groups in our dataset.
Our analysis revealed IBD scores of 1.465 and 0.817 for Finnish and British groups, consistent with previous analyses. The IBD score of all of the groups was normalized relative to the Finnish group (Fig. 4a and Supplementary Information 12). Our study includes many groups with small population sizes and it is expected that endogamy paired with small population size will greatly increase IBD scores. We found that indigenous and tribal groups had IBD scores that were skewed upwards from non-tribal groups (Fig. 4b). Notably, we found that a number of Asian groups with large urban populations have IBD scores above or close to that of the Finnish population. For example, samples from an outpatient hospital in Chennai, a city with a census size of 9 million, had an IBD score that was approximately 1.3 times greater than the score for the Finnish group.
Human knockouts
Homozygous loss-of-function alleles found in humans give us the opportunity to assess the phenotypic effect of specific gene loss and can provide important information about opportunities for treating disease,. To assess the contents of our dataset, we examined high-confidence protein-truncating variants (PTVs). We found 17,566 PTVs with at least 1 PTV in approximately 43% of all protein-coding genes (n = 8,766; Fig. 4c). Among the PTVs, most were heterozygous variants unique to our dataset (n = 8,799; Fig. 4d), similar to the PTV data from ExAC (67% singletons). A smaller number were homozygous and had been reported in gnomAD, dbSNP or 1000 Genomes Project (n = 856). In addition, within our dataset were 121 homozygous PTVs that have not previously been reported (Supplementary Table 5). These novel homozygous PTVs were mostly found in groups with high IBD scores such as the Jarawa and Onge from the Andaman Islands (Fig. 4e). The novel homozygous PTVs include an allele of the ABCA7 gene, Q2010*, that is found in only the Aeta population (Fig. 4f). Heterozygosity for loss-of-function alleles of ABCA7 has been shown to increase susceptibility to Alzheimer’s disease in European populations.
Imputation panel
We carried out preliminary work to evaluate the utility of the pilot dataset for imputation. For this analysis, we downsampled whole-genome sequence data from South Asian, Southeast Asian and Northeast Asian population groups (see Supplementary Table 1a for samples included in each of these geographically defined sets) 30× to the genotypes represented on the Illumina Global Screening Array v.1 genotyping array, and compared the imputation using either phase 3 of the 1000 Genomes Project or the GAsP reference panels. We found, as described by Illumina, that imputation accuracy of the 1000 Genomes Project reference panel is consistently well below 90% for east Asian and south Asian samples whereas using the GAsP reference panel we achieved accuracies ranging from 93 to 95%. To accelerate evaluation and broad utility, we have placed the data on the Michigan Imputation Server (https://imputationserver.sph.umich.edu/index.html).
Discussion
Understanding the genetic basis of human disease will benefit from an increase in the number and scale of disease-association studies that are carried out in Asian populations. In the pilot phase of the GenomeAsia project, the sample set that we analysed allowed us to address a wide range of questions regarding the history of specific Asian population groups and to map out strategies for additional sequencing efforts. We plan for a staged and coordinated approach, to include the generation of genomic population-specific reference datasets and imputation panels, and use this approach for the production of custom SNP arrays as a catalyst for disease-association studies. This approach is particularly useful in founder populations, such as recent studies in the founder populations of Finland, as well as other populations. This will be particularly valuable in Asia,, which has founder effects that have not only previously been demonstrated in isolated populations, but are also evident in major urban centres.
Analysis of the GAsP dataset allows us to map out strategies for efforts focused on specific population centres in Asia as well as the generation of important tools that will increase our understanding of how genetic variants affect disease susceptibility and drug responses. The dataset improves the ability to filter out low-probability candidates for highly penetrant disorders, to identify putatively pathogenic variants that are found at high frequency in particular populations and improve the ability to infer pathogenicity of identified variants. The identification of novel homozygous PTVs in this study expands the catalogue of genes in which homozygous loss of function appears to be tolerated and, when combined with phenotype information, this will provide important biological insights into gene function. The ability to define gene function in humans through the study of the phenotypic effects of loss-of-function mutations is becoming an increasingly valuable approach and the study of additional variants and populations in which homozygosity occurs at high rates will add to the global resources for carrying out human knockout studies.
Data reporting
No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to the allocation during analysis.
Samples
We accessed publicly available high-coverage, whole-genome FASTQ files from previous studies of human genetic variation– and combined these with 1,267 high-coverage genomes generated as part of this project. Full details on the samples chosen for sequencing and the informed consent processes for these samples can be found in Supplementary Information 1. We restricted our analyses to genomes generated using Illumina short-read sequencing technology.
Whole-genome sequencing
Whole-genome sequencing libraries were prepared using standard protocols (Illumina) and sequenced on Illumina Hiseq 2500/4000 or X10 machines. We obtained paired-end (2 × 100 bp or 2 × 150 bp) for each sample.
Filtering, alignment and variant calling
We aligned the Illumina short-read sequences to the GRCh37+decoy reference genome with BWA-mem using the default parameters. Putative PCR duplicates were flagged using SAMBLASTER. The SAM outputs were converted to BAM format, and sorted by chromosomal coordinates using Sambamba, and all BAM files for the same samples were merged.
The sex of the samples was inferred from the coverage of the autosomes and the sex chromosomes, and confirmed from the submitted metadata with the samples. All samples that had an average coverage less than 20-fold or for which we found a difference in the inferred and reported sex were removed from further analysis. We used verifyBamID to identify contamination using the chip-free mode and samples for which swaps or contamination was identified were removed from subsequent analyses. A contamination level of 3% was used as a cut-off, and this left us with 1,739 samples that were used for all downstream analyses.
We identified the single-nucleotide substitutions and small indels variants in the 1,739 samples using the reference model (gVCF-based) workflow for joint analysis in GATK. Variants were called individually in each sample using the HaplotypeCaller in ‘-ERC GVCF’ mode to produce a record of genotype likelihoods and annotations at each site in the genome. Multi-allelic variants are reported in the GenomeAsia browser but were not included in the analysis. A gVCF file was created for every sample, and a subsequent joint genotyping analysis of all gVCFs was done to identify the variants in the cohort. We followed the GATK-recommended best practices for variant recalibration to create a final VCF file and recalibrated the variants to select 99% of the true sites from the training set for VQSR. The VCF files were zipped using bgzip and indexed using tabix.
Identification of first-degree relative pairs
Several of the reported analyses require filtering to remove related samples. We used KING to identify such first-degree relative pairs. We first used vcftools and plink to convert the VCF file into the required input format for KING. The estimated kinship coefficient was restricted to 0.177–0.354 as described in the KING manual to identify the first-degree relative pairs, and the results were confirmed from the submitted metadata. The number of unrelated samples by country-of-origin is shown in Supplementary Table 1.1.
Quantifying population structure and changes in population size
We restricted our attention to 7,966,132 autosomal markers (that is, SNPs) with MAF ≥ 0.01 and call rate ≥ 98%. In some analysis, severe linkage disequilibrium pruning was applied as follows: sliding windows of size 50 (that is, the number of markers used for linkage disequilibrium testing at a time) and window increments of 5 markers; for any pair of SNPs in a window, the first marker of the pair was discarded if r2 > 0.2. After linkage disequilibrium pruning, 1,089,227 SNPs were retained for analysis. All data-filtering procedures were conducted in PLINK v.1.9.
Analyses of population structure was performed using the quality-control-positive linkage-disequilibrium-pruned set of 1,089,227 autosomal SNPs. Principal component analysis (PCA) was conducted across all available populations in EIGENSTRAT v.6.1.4. Results were visualized in Tableau v.9.3. We applied unsupervised hierarchical clustering of individuals using the maximum likelihood method implemented in ADMIXTURE v.1.3.0 using default input parameters. The ‘--cv’ flag was adopted to perform the cross-validation procedure and to calculate the optimal k value.
We used MSMC to estimate changes in population size and split times. This analysis used two different phased genome datasets (using Shapeit v.2 and Eagle2). The details for the phasing are described in Supplementary Information 4. Chromosome 6 was excluded from the analysis owing to possible phasing errors in the HLA region. We used four haplotypes (two individual genomes) for estimating changes in population size in a population and eight haplotypes (two genomes from each of a pair of populations) for the estimation of population split times. We assumed a mutation rate of μ = 1.25 × 10−8 per site per generation and an average generation time of 29 years, as in previous studies,.
Comparison with 1000 Genomes Project genotype calls
We filtered the variant calls to include only biallelic SNPs with <10% missing genotype calls that were within the 1000 Genomes Project strict mask (available at ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/supporting/accessible_genome_masks/20141020.strict_mask.whole_genome.bed). Then, for each of the 119 overlapping samples considered individually, we calculated variant discordance rates for those filtered SNPs that (1) had a genotype call in both the 1000 Genomes Project data and the GAsP data; and (2) had a ‘variant’ call (that is, a non-homozygous reference genotype call) in at least one of the datasets. These discordance rates were then stratified by the estimated MAF in the GAsP dataset.
Patterns of allele sharing
We used a parsimony-based analysis of allele sharing that focused on SNPs that were not present in sub-Saharan Africans or in archaic humans (further details are provided in Supplementary Information 8).
Archaic admixture
We used a method similar to the ‘enhanced’ D-statistic approach, to estimate levels of Neanderthal and Denisovan ancestry in each non-African sample. The estimates were calibrated assuming 0% Denisovan ancestry in the British population, 4% Denisovan ancestry in the Papuan population and 2% Neanderthal ancestry in the British population (full details are provided in Supplementary Information 9).
Determination of high-quality variants for medically related analyses
High-quality variants were defined as variants that (1) had a read-depth ≥ 5 and genotype-quality ≥ 20; (2) were contained in the high-confidence regions as described by Genome in a Bottle (ftp://ftp-trace.ncbi.nlm.nih.gov/giab/ftp/release/NA12878_HG001/NISTv3.3.2/GRCh37/supplementaryFiles/HG001_GRCh37_GIAB_highconf_CG-IllFB-IllGATKHC-Ion-10X-SOLID_CHROM1-X_v.3.3.2_highconf.bed) and (3) passed the gnomAD_Filter. Variant annotation was carried out using SnpEff (v.4.1).
IBD scores
Groups with at least two samples were considered for analysis. We restricted our analysis to genomic regions with high-confidence calls and removed related samples based on reported relationship, kinship, PCA and IBD analyses. The scores given in the figure are relative ratios compared to that of the Finnish group.
PTVs
PTVs are defined as high-quality variants that were annotated as having a strong impact on the protein (such as frameshifts, essential splice sites or premature stop codons). We restricted calls to high-confidence regions determined by Genome in a Bottle as described above and filtered for high-confidence PTVs using the LOFTEE program. We used a similar strategy for additional filtering of variants as proposed previously and flagged variants with ≤7 reads covering the variant site; ≤80% of reads had the variant, were not in the bottom 1 percentile of phyloP or gerpRS scores and for which the affected transcripts made up less than 50% of all expression as specified by GTEx.
Enriched medically relevant variants
We compared variant allele counts for Asian and Oceania samples from the GenomeAsia cohort to allele counts present in non-Asian gnomAD samples (European (non-Finnish), European (Finnish), Latino, African or other) for variants found in a set of 124 medically relevant genes. The genes used were 115 genes used for prenatal screening as well as the cancer-associated genes BRCA1, BRCA2, TP53, MEN1, MLH1, MSH2, MSH6, PMS1 and PMS2A. A Fisher’s exact test was used to calculate variations that were significantly overrepresented in the GenomeAsia subsamples and corrected for multiple testing using the Bonferroni method. We further accessed variants for these genes that had not previously been reported. All variants were further filtered as being damaging as determined by having a high impact on the protein (stop codon, essential splice site or frameshift mutation) or were predicted to be damaging by the Polyphen2 program. A cumulative comparison of allele counts for all over-represented and novel variants was performed and compared to non-Asian gnomAD to calculate a P value, odds ratio and relative difference in cumulative allele frequency (GenomeAsia cumulative allele frequency minus gnomAD non-Asian allele frequency). Reported P values were corrected for multiple testing using the Bonferroni method.
Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at 10.1038/s41586-019-1793-z.
References 70
- 1.
Popejoy AB, Fullerton SM. Genomics is failing on diversity. Nature. 2016;538:161-164.
Not in our library10.1038/538161a
- 2.
Martin AR, et al. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat. Genet. 2019;51:584-591.
Not in our library10.1038/s41588-019-0379-x
- 3.
The Genome of the Netherlands Consortium. Whole-genome sequence variation, population structure and demographic history of the Dutch population. Nat. Genet. 2014;46:818-825.
Not in our library10.1038/ng.3021
- 4.
The 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature. 2015;526:68-74.
Not in our library10.1038/nature15393
- 5.
Gurdasani D, et al. The African Genome Variation Project shapes medical genetics in Africa. Nature. 2015;517:327-332.
Not in our library10.1038/nature13997
- 6.
- 7.
Sudmant PH, et al. An integrated map of structural variation in 2,504 human genomes. Nature. 2015;526:75-81.
Not in our library10.1038/nature15394
- 8.
Mallick S, et al. The Simons Genome Diversity Project: 300 genomes from 142 diverse populations. Nature. 2016;538:201-206.
Not in our library10.1038/nature18964
- 9.
Mitt M, et al. Improved imputation accuracy of rare and low-frequency variants using population-specific high-coverage WGS-based imputation reference panel. Eur. J. Hum. Genet. 2017;25:869-876.
Not in our library10.1038/ejhg.2017.51
- 10.
Southam L, et al. Whole genome sequencing and imputation in isolated populations identify genetic associations with medically-relevant complex traits. Nat. Commun. 2017;8:15606.
Not in our library10.1038/ncomms15606
- 11.
- 12.
Lencz T, et al. High-depth whole genome sequencing of an Ashkenazi Jewish reference panel: enhancing sensitivity, accuracy, and imputation. Hum. Genet. 2018;137:343-355.
Not in our library10.1007/s00439-018-1886-z
- 13.
Ebenesersdóttir SS, et al. Ancient genomes from Iceland reveal the making of a human population. Science. 2018;360:1028-1032.
Not in our library10.1126/science.aar2625
- 14.
Njølstad PR, et al. Roadmap for a precision-medicine initiative in the Nordic region. Nat. Genet. 2019;51:924-930.
Not in our library10.1038/s41588-019-0391-1
- 15.
Bentley AR, Callier S, Rotimi C. The emergence of genomic research in Africa and new frameworks for equity in biomedical research. Ethn. Dis. 2019;29:179-186.
Not in our library10.18865/ed.29.s1.179
- 16.
Nagai A, et al. Overview of the BioBank Japan Project: study design and profile. J. Epidemiol. 2017;27:S2-S8.
Not in our library10.1016/j.je.2016.12.005
- 17.
Chen Z, et al. China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. Int. J. Epidemiol. 2011;40:1652-1666.
Not in our library10.1093/ije/dyr120
- 18.
Price AL, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 2006;38:904-909.
Not in our library10.1038/ng1847
- 19.
Schiffels S, Durbin R. Inferring human population size and separation history from multiple genome sequences. Nat. Genet. 2014;46:919-925.
Not in our library10.1038/ng.3015
- 20.
Alexander DH, Novembre J, Lange K. Fast model-based estimation of ancestry in unrelated individuals. Genome Res. 2009;19:1655-1664.
Not in our library10.1101/gr.094052.109
- 21.
The HUGO Pan-Asian SNP Consortium. Mapping human genetic diversity in Asia. Science. 2009;326:1541-1545.
Not in our library10.1126/science.1177074
- 22.
Aghakhanian F, et al. Unravelling the genetic history of Negritos and indigenous populations of Southeast Asia. Genome Biol. Evol. 2015;7:1206-1215.
Not in our library10.1093/gbe/evv065
- 23.
Reich D, et al. Denisova admixture and the first modern human dispersals into Southeast Asia and Oceania. Am. J. Hum. Genet. 2011;89:516-528.
Not in our library10.1016/j.ajhg.2011.09.005
- 24.
Mijares ASB. The early Austronesian migration to Luzon: perspectives from the Peñablanca cave sites. Bull. Indo-Pacific Prehist. Assoc. 2006;26:72-78.
Not in our library
- 25.
Détroit F, et al. A new species of Homo from the Late Pleistocene of the Philippines. Nature. 2019;568:181-186.
Not in our library10.1038/s41586-019-1067-9
- 26.
Sankararaman S, Mallick S, Patterson N, Reich D. The combined landscape of Denisovan and Neanderthal ancestry in present-day humans. Curr. Biol. 2016;26:1241-1247.
Not in our library10.1016/j.cub.2016.03.037
- 27.
Reich D, Thangaraj K, Patterson N, Price AL, Singh L. Reconstructing Indian population history. Nature. 2009;461:489-494.
Not in our library10.1038/nature08365
- 28.
Majumder PP, Basu A. A genomic view of the peopling and population structure of India. Cold Spring Harb. Perspect. Biol. 2015;7:a008540.
Not in our library10.1101/cshperspect.a008540
- 29.
- 30.
NHLBI GO Exome Sequencing Project (ESP). Exome Variant Server. http://evs.gs.washington.edu/EVS/ (version: ESP6500SI-V2) (2015).
Not in our library
- 31.
Piton A, Redin C, Mandel JL. XLID-causing mutations and associated genes challenged in light of data from large-scale human exome sequencing. Am. J. Hum. Genet. 2013;93:368-383.
Not in our library10.1016/j.ajhg.2013.06.013
- 32.
Chapla A, et al. Maturity onset diabetes of the young in India - a distinctive mutation pattern identified through targeted next-generation sequencing. Clin. Endocrinol. 2015;82:533-542.
Not in our library10.1111/cen.12541
- 33.
Mohan, V., et al. Comprehensive genomic analysis identifies pathogenic variants in Maturity-Onset Diabetes of the Young (MODY) patients in south India. BMC Med Genet.19, 22 (2018).
Not in our library10.1186/s12881-018-0528-6
- 34.
Sherry ST, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29:308-311.
Not in our library10.1093/nar/29.1.308
- 35.
Moayyeri A, Hammond CJ, Hart DJ, Spector TD. The UK Adult Twin Registry (TwinsUK Resource). Twin Res. Hum. Genet. 2013;16:144-149.
Not in our library10.1017/thg.2012.89
- 36.
Roden DM, George AL. The genetic basis of variability in drug responses. Nat. Rev. Drug Discov. 2002;1:37-44.
Not in our library10.1038/nrd705
- 37.
Ashley EA, et al. Clinical assessment incorporating a personal genome. Lancet. 2010;375:1525-1535.
Not in our library10.1016/s0140-6736(10)60452-7
- 38.
Johnson JA, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 2011;90:625-629.
Not in our library10.1038/clpt.2011.185
- 39.
Karczewski KJ, Daneshjou R, Altman RB. Chapter 7: Pharmacogenomics. PLOS Comput. Biol. 2012;8:e1002817.
Not in our library10.1371/journal.pcbi.1002817
- 40.
Urban TJ, Goldstein DB. Pharmacogenetics at 50: genomic personalization comes of age. Sci. Transl. Med. 2014;6:220ps1.
Not in our library10.1126/scitranslmed.3005237
Cited by papers we hold 9
- A deep catalogue of protein-coding variation in 983,578 individuals · 2024Corrected
- A multi-ancestry polygenic risk score improves risk prediction for coronary artery disease · 2023No notice
- Understanding signatures of positive natural selection in human zinc transporter genes · 2022Not checked
- A guide for the diagnosis of rare and undiagnosed disease: beyond the exome · 2022No notice
- Use of race, ethnicity, and ancestry data in health research · 2022No notice
- Genomic analyses of 10,376 individuals in the Westlake BioBank for Chinese (WBBC) pilot project · 2022No notice
- Genetic profiles of 103,106 individuals in the Taiwan Biobank provide insights into the health and history of Han Chinese · 2021No notice
- Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2 · 2021No notice
- Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions · 2020No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.